Skip to main content

Evommune, Inc 8-K, filed Nov 17, 2026

Evommune, Inc. (EVMN)

8-K 2026-11-17 For: 2026-11-13
View Original
Added on November 17, 2026

About this 8-K

Evommune, Inc filed this 8-K on November 17, 2026, reporting on events of November 13, 2026.

Evommune approved cash retention awards for its Chief Executive Officer, Chief Financial Officer, and Chief Business & Legal Officer, and repriced underwater stock options to $7.63 per share, covering 3,692,840 shares. AI summary

Items reported

  • Item 5.02: Director or officer change, or executive pay